JP2024519814A5 - - Google Patents

Info

Publication number
JP2024519814A5
JP2024519814A5 JP2023571295A JP2023571295A JP2024519814A5 JP 2024519814 A5 JP2024519814 A5 JP 2024519814A5 JP 2023571295 A JP2023571295 A JP 2023571295A JP 2023571295 A JP2023571295 A JP 2023571295A JP 2024519814 A5 JP2024519814 A5 JP 2024519814A5
Authority
JP
Japan
Prior art keywords
independently
salt
compound
target
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023571295A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024519814A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/029535 external-priority patent/WO2022245759A2/en
Publication of JP2024519814A publication Critical patent/JP2024519814A/ja
Publication of JP2024519814A5 publication Critical patent/JP2024519814A5/ja
Pending legal-status Critical Current

Links

JP2023571295A 2021-05-17 2022-05-17 指向性コンジュゲーション技術のための薬剤及びコンジュゲート生成物 Pending JP2024519814A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163189522P 2021-05-17 2021-05-17
US63/189,522 2021-05-17
PCT/US2022/029535 WO2022245759A2 (en) 2021-05-17 2022-05-17 Agents for directed conjugation techniques and conjugated products

Publications (2)

Publication Number Publication Date
JP2024519814A JP2024519814A (ja) 2024-05-21
JP2024519814A5 true JP2024519814A5 (cg-RX-API-DMAC10.html) 2025-05-23

Family

ID=84140970

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023571295A Pending JP2024519814A (ja) 2021-05-17 2022-05-17 指向性コンジュゲーション技術のための薬剤及びコンジュゲート生成物

Country Status (11)

Country Link
US (1) US20240252674A1 (cg-RX-API-DMAC10.html)
EP (1) EP4340891A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024519814A (cg-RX-API-DMAC10.html)
KR (1) KR20240012380A (cg-RX-API-DMAC10.html)
CN (1) CN117750979A (cg-RX-API-DMAC10.html)
AU (1) AU2022275832A1 (cg-RX-API-DMAC10.html)
CA (1) CA3219517A1 (cg-RX-API-DMAC10.html)
IL (1) IL307799A (cg-RX-API-DMAC10.html)
MX (1) MX2023013272A (cg-RX-API-DMAC10.html)
PH (1) PH12023553154A1 (cg-RX-API-DMAC10.html)
WO (1) WO2022245759A2 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12023553152A1 (en) * 2021-05-17 2024-03-11 Biohaven Therapeutics Ltd Compositions including conjugated therapy enhancers
WO2026150353A2 (en) 2025-01-11 2026-07-16 Biohaven Therapeutics Ltd. Antibody-drug conjugates for delivering cytotoxic agents

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7226577B2 (en) * 2003-01-13 2007-06-05 Bracco Imaging, S. P. A. Gastrin releasing peptide compounds
US20140079636A1 (en) * 2012-04-16 2014-03-20 Dinesh U. Chimmanamada Targeted therapeutics
AU2014372833B2 (en) * 2013-12-23 2019-08-22 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP)
WO2017042944A1 (ja) * 2015-09-10 2017-03-16 国立大学法人山梨大学 フィラデルフィア染色体陽性(Ph+)急性リンパ性白血病(ALL)の治療薬又は治療方法
CA3061467A1 (en) * 2017-04-28 2019-10-24 Ajinomoto Co., Inc. Compound having affinity substance to soluble protein, cleavable portionand reactive group, or salt thereof
SG11202000628XA (en) * 2017-07-26 2020-02-27 Kleo Pharmaceuticals Inc Universal abt compounds and uses thereof
JP7404230B2 (ja) * 2017-09-18 2023-12-25 トラスティーズ オブ ボストン ユニバーシティ ネトーシスおよび好中球活性化を処置するための方法
WO2019241609A1 (en) * 2018-06-15 2019-12-19 Trustees Of Boston University Polypeptide compositions and methods for site-specific targeting of therapeutic agents
CA3143513A1 (en) * 2019-07-03 2021-01-07 Kleo Pharmaceuticals, Inc. Cd38-binding agents and uses thereof

Similar Documents

Publication Publication Date Title
JP6942147B2 (ja) Mt1−mmpに対して特異的な二環式ペプチド−毒素コンジュゲート
EP2651964B1 (en) Cross-linked peptides and proteins, methods of making same, and uses thereof
JP2022517698A (ja) インテグリンαvβ3に特異的な二環式ペプチドリガンド
JP2022514687A (ja) Pd-l1に特異的な二環式ペプチドリガンド
CN110114075A (zh) 含有二硫化物的细胞穿透肽及其制备和使用方法
JP2021507909A (ja) EphA2に特異的な二環ペプチドリガンド
JP2020514403A (ja) Mt1−mmpに結合するためのペプチドリガンド
EP3432935B1 (en) Site-specific bio-conjugation methods and compositions useful for nanopore systems
AU2022234694B2 (en) Compound or salt thereof, and antibody obtained using same
JP7794789B2 (ja) タンパク質精製のための超分子フィラメント集合体
JP2024521092A5 (cg-RX-API-DMAC10.html)
AU2022208654B2 (en) Compound or salt thereof, and antibody produced using same
US8829157B2 (en) Process for the synthesis of cyclic heptapeptide
CN105254655B (zh) 一种基于bodipy的荧光氨基酸及其合成方法与应用
JP6977058B2 (ja) ピクテ・スペングラー反応を介して得られたタグ付けヌクレオシドを用いたシーケンシング反応のための方法
JP2024519814A (ja) 指向性コンジュゲーション技術のための薬剤及びコンジュゲート生成物
US12351619B2 (en) Serum albumin-binding fibronectin type III domains and uses thereof
JPH06239898A (ja) 免疫抱合体の調製法
WO2020195302A1 (ja) 細胞膜透過性環状ペプチド作製用リンカー分子、及びその利用
WO2022116141A1 (zh) 抗体药物偶联物、其中间体、制备方法及应用
JPWO2016060096A1 (ja) ホスホリルコリン基含有化合物およびホスホリルコリン複合体
JP2023501720A5 (cg-RX-API-DMAC10.html)
CN107935895B (zh) 化合物及其制备方法和应用
Tessier et al. Chapter IV. Ethynylation of Cysteine Residues: From Peptides to Proteins in Vitro and in Living Cells
CN116854785A (zh) 位点特异性修饰和标记的抗病毒肽氰病毒素n